Study on the Value of miR6503-5p Combined with PGR in the Diagnosis of Early Gastric Cancer

2021 ◽  
Vol 7 (5) ◽  
pp. 1516-1521
Author(s):  
Xuli Guo ◽  
Lezhong Yuan ◽  
Xia Yuan ◽  
Xiaohong Guo ◽  
Jun Li ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Early Gastric Cancer ◽  
Roc Curve ◽  
Serum Levels ◽  
Stage I ◽  
Stage Ii ◽  
Control Group ◽  
Cancer Group ◽  
Significant Difference ◽  
Gastric Cancer Group

Objective To investigate the value of serum miRNA 6503-5p (miR6503-5p) combined with pepsinogen ratio (PGR) in the diagnosis of early gastric cancer. Methods: 94 patients (gastric cancer group) with gastric cancer confirmed by pathological examination and 90 patients with chronic atrophic gastritis collected by Department of Pathology in our hospital were selected as the control group, the serum levels of pepsinogen (PG I, PG II) and miR6503-5p were measured in the two groups, and the value of the two indexes in the diagnosis of gastric cancer was analyzed by ROC. Results: The serum levels of miR6503-5p in gastric cancer group were significantly higher than those in control group (P<0.05), the serum levels of PG I and PGR in gastric cancer group were significantly lower than those in control group (P<0.05), the serum levels of miR6503-5p in stage II gastric cancer group were significantly higher than those in stage I patients with statistically significant difference (P<0.05), and the serum levels of PG I and PGR in stage II gastric cancer group were significantly lower than those in stage I patients with statistically significant difference (P<0.05). The serum levels of PG I, PG II and PGR in the patients with highly and moderately differentiated gastric cancer were not significantly different from those in the patients with poorly and undifferentiated gastric cancer, with no statistically significant different (P>0.05); the serum levels of miR6503-5p in the patients with highly and moderately differentiated gastric cancer were significantly lower than those in the patients with poorly and undifferentiated gastric cancer, with statistically significant difference (P<0.05); the sensitivity of miR6503-5p in diagnosing gastric cancer was 81.33%, the specificity was 71.09%, the area under the ROC curve was 0.767; the sensitivity of PGR in diagnosing gastric cancer was 85.81%, the specificity was 78.40%, and the area under the ROC curve was 0.827. The sensitivity of serum miR6503-5p combined with PGR was 96.40%, the specificity was 85.44%, and the area under the ROC curve was 0.920. Conclusion The miR 6503-5p combined with PGR has high sensitivity and specificity in the diagnosis of gastric cancer and is worthy of clinical application in the screenof patient with early gastric cancer.

Serum Levels of OPG and MIP-1α in Untreated Multiple Myeloma Patients. Correlations with Staging, Survival and Bone Disease.

Blood ◽  
2005 ◽  
Vol 106 (11) ◽  
pp. 5074-5074
Author(s):  
Argyro Papadogiannis ◽  
Marie-Cristine Kyrtsonis ◽  
Theodoros P. Vassilakopoulos ◽  
Tatiana Tzenou ◽  
Antonios G. Antoniadis ◽  
...  
Keyword(s):  
Bone Disease ◽  
Staging System ◽  
Serum Levels ◽  
High Serum ◽  
Stage I ◽  
Stage Ii ◽  
Stage Iii ◽  
Bone Lesions ◽  
Disease Biology ◽  
Significant Difference

Abstract Cytokines, such as MIP-1a (macrophage inhibiting factor) and OPG (osteoprotegerin) are assumed to play a role in MM disease biology and bone disease, by mechanisms that are still under investigation. MIP-1a is constitutively secreted by myeloma cells, plays a possible role in the development of MM bone lesions, enhance MM cell adhesion to stromal cells and its serum levels have been recently related to survival in MM. OPG is a soluble decoy receptor which acts as a soluble receptor antagonist that prevents osteoclasts activation and the development of bone disease. Reported findings on serum OPG levels in MM patients are controversial as well as its possible role in the biology of the disease. In order to investigate the possible relationship of MIP-1a and OPG levels in MM patients with prognosis and bone disease, we determined by ELISA serum MIP-1a and OPG levels in 20 MGUS, 82 MM patients and 27 healthy individuals (HI). Both cytokines were determined by ELISA (R&D, Quantikine, USA) in frozen sera collected at dignosis, before treatment. The median age of MM patients was 69 years (44–84) and 50% were males. MM patients’ stage was as follows: 23 stage I, 28 stage II, 31 stage III according to Durie-Salmon staging system and 27 stage I, 17 stage II, 35 stage III according to the International Scoring System (ISS). In HI median MIP-1a was 28 pg/ml (15–54) and median OPG 1600 pg/ml (450–4600). In subjects with MGUS, median MIP-1a was 34 pg/ml (17–58) and median OPG 2300 pg/ml (820–6200). In MM patients, median pretreatment serum MIP-1a was 32 pg/ml (16–100) and OPG 3000 pg/ml (820–25000). No statistical significant difference was observed between HI, MGUS and MM patients with regard to MIP-1a levels but for OPG levels differences between HI and MM patients and between MGUS and MM patients were both significant (0.01 and 0.05 respectively). No relationship was found between MIP-1a or OPG levels and bone disease. However, there was a trend for longer survival in patients with MIP-1a or OPG levels lower than median (5-year overall survival 60 ± 12 vs 38 ± 14, p=0.08 and 66 ± 13 vs 29 ± 13, p=0.07 respectively). In addition MIP-1a levels were correlated with ISS stage: MIP-1a levels were 28.3±11.3 in ISS stage 1, 29.8±11.1 in ISS stage 2, 39±19.2 in ISS stage 3 (p=0.02). In conclusion, in our experience serum OPG levels are higher in MM patients than in MGUS or HI, MIP-1a levels are correlated with the ISS stage and both high serum MIP-1a and OPG levels at diagnosis are related with a shorter survival.

scholarly journals Overexpression of Semaphorin-3A and Semaphorin-4D in the Peripheral Blood from Newly Diagnosed Patients with Chronic Lymphocytic Leukemia

2019 ◽  
Author(s):  
Somayeh Parsa ◽  
Sedigheh Sharifzadeh ◽  
Ahmad Monabati ◽  
Noorossadat Seyyedi ◽  
Reza Ranjbaran ◽  
...  
Keyword(s):  
Chronic Lymphocytic Leukemia ◽  
Peripheral Blood ◽  
Healthy Subjects ◽  
Fold Change ◽  
Lymphocytic Leukemia ◽  
Stage I ◽  
Stage Ii ◽  
Control Group ◽  
Newly Diagnosed ◽  
Significant Difference

Background: Semaphorins play prominent roles in physiological and pathological processes such as vascular development, tumor growth and immune responses. Semaphorins have different roles in various kinds of cancers, but there is no study concerning their expression in the chronic lymphocytic leukemia (CLL). This study aimed to assess the SEMA3A, SEMA4A and SEMA4D expression in patients with CLL.  Materials and Methods: Peripheral blood specimens were collected from 30 newly-diagnosed untreated patients with CLL and 30 healthy subjects as a control group. The SEMA3A, SEMA4A and SEMA4D expression was determined by real-time PCR method.  Results: The fold change expression of SEMA3A and SEMA4D was 7.58 ± 2.66 and 3.20 ± 0.99 in patients with CLL, and was 1.01 ± 0.31 and 1.00 ± 0.27 in healthy subjects, respectively. The CLL patients expressed higher amounts of SEMA3A and SEMA4D in comparison with healthy subjects (P<0.02 and P<0.03, respectively). The fold change expression of SEMA3A in patients with stage II (11.12 ± 5.35) was also higher than patients with stage I (4.49 ± 1.61, P<0.05). No significant difference was also observed in the expression of SEMA4A and SEMA4D between patients with stage I and stage II CLL. In both CLL and control groups, the fold change expression of SEMA3A was higher in men than in women (P<0.03 and P<0.02, respectively). Conclusion: The results of the study indicated elevated expression of the SEMA3A and SEMA4D in patients with CLL. The SEMA3A expression was influenced by tumor stage and gender of participants. 

The effect of CTLA-4 and CD28 gene variants and circulating protein levels in patients with gastric cancer

2017 ◽  
Vol 42 (5) ◽  
Author(s):  
Soykan Arikan ◽  
Alper Gümüş ◽  
Özlem Küçükhüseyin ◽  
Cihan Coşkun ◽  
Saime Turan ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Cancer Patients ◽  
Control Group ◽  
Protein Levels ◽  
Cancer Group ◽  
Pcr Rflp ◽  
Gastric Cancer Patients ◽  
Turkish Patients ◽  
Circulating Levels ◽  
Gastric Cancer Group

AbstractObjective:Gastric cancer is one of the most common malignancies worldwide. The risk factors for gastric cancer include environmental and genetic factors. Inflammation and the immune system are known to contribute to the development of the gastric cancer. We examined the influence of critical polymorphisms of CTLA-4 and CD28 genes and circulating protein levels on the etiology of gastric cancer.Methods:Genotyping of SNPs was performed in 55 gastric cancer patients and 105 healthy individuals using the PCR-RFLP method, and circulating levels of sCTLA-4 and sCD28 were measured.Results:There were no significant differences in the genotype and allele distributions of the evaluated SNPs [CTLA-4-318 C>T (rs5742909), CTLA-4+49 A>G (rs231775), CD28 C>T (rs3116496)] between gastric cancer patients and controls (p=0.36, p=0.78, and p=0.80, respectively). The circulating levels of sCTLA-4 and sCD28 were significantly different between the gastric cancer group and the control group (p<0.001 and p<0.001, respectively).Conclusion:The present results suggest that the CTLA-4 and CD28 gene polymorphisms that were evaluated do not play an important role in Turkish patients with gastric cancer. However, sCTLA4 and sCD28 levels were higher in cancer patients and may be useful as an auxiliary parameter in the diagnosis and monitoring of gastric cancer.

scholarly journals Discovering Biomarkers in Gastric Cancer by Urine Metabolomics

2021 ◽  
Author(s):  
Yuan Kong ◽  
Hongya Zhang ◽  
Shuang Li ◽  
Jian Suo ◽  
Shaopeng Zhang ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Cluster Analysis ◽  
Early Gastric Cancer ◽  
Partial Least Square ◽  
Least Square ◽  
Urine Samples ◽  
Diagnostic Ability ◽  
Healthy Group ◽  
Cancer Group ◽  
Gastric Cancer Group

Abstract IntroductionGastric cancer is one of the most common gastrointestinal tumors, ranking forth in incidence and second in mortality worldwide. Discovering molecular biomarkers for early gastric cancer diagnosis is of great importance. MethodsUrine and related clinical data of 40 patients with gastric cancer (20 in advanced stage and 20 in early stage) and 20 healthy volunteers from Jilin University First Hospital were collected. Liquid chromatography-mass spectrometry (LC-MS) was used to detect urine samples and the metabolic differences between the three groups of urine samples were analyzed. The principal component analysis was performed after data processing, and different metabolites were found using analysis of variance. Partial least square discriminant analysis was performed to further narrow the range of different metabolites. The precise mass to charge ratios of different metabolites were imported into the Human Metabolomics Database (HMDB). Finally, the identified different metabolites were further screened by cluster analysis and ROC curve. ResultsUrine samples of the healthy group (NOR), the early gastric cancer group (EGC), and the advanced gastric cancer group (AGC) were different metabolites. 324 statistically significant metabolites are screened out. The cluster analysis showed 7-Methylguanine, vinylacetylglycine, butyric acid, 4-Vinylphenol sulf,
5`-biotinyl-AMP, and 3-Amino-2-piperido in EGC, AGC and NGO were similar. 7-Methylguanine, vinylacetylglycine and 4-Vinylphenolsulfate had good diagnostic ability in EGC and NOR (p<0.05), and gastric cancer and NOR (p<0.05). ConclusionDifferences in the metabolites in urine between the early gastric cancer group and the healthy group were found. 7-Methylguanine, Vinylacetylglycine, and 4-Vinylphenolsulfate have good diagnostic ability and may be potential biomarkers of early gastric cancer.

SERUM PEPSINOGEN I LEVELS IN GASTRIC CANCER

2013 ◽  
pp. 43-49
Author(s):  
Thi Minh Tam Phan ◽  
Thi Thu Huong Hoang ◽  
Anh Tuyen Nguyen ◽  
Thi Phuong Anh Le ◽  
Nguyen Tuong Van Ha
Keyword(s):  
Gastric Cancer ◽  
Predictive Value ◽  
Area Under The Curve ◽  
Control Group ◽  
Serum Pepsinogen ◽  
Pepsinogen I ◽  
Cancer Group ◽  
And Control ◽  
Group Serum ◽  
Gastric Cancer Group

Objective: Identification of serum Pepsinogen I levels in gastric cancer. Materials and Methods: Serum pepsinogen I levels was measured by enzym-linked immunosorbent assay (ELISA) on 32 patients in the gastric cancer group diagnosed by endoscopy and histology and control group of 30 patients with functional dyspepsia on endoscopy Using the cut-off value: PGI ≤ 70 ng/ml for gastric cancer. Results: Median Pepsinogen I levels in gastric cancer group was 41.07 ng / ml (25% quartile: 27.83 ng / ml, 75% quartile: 61.57 ng/ml) was significantly lower in control group: 102.03 ng / ml (25% quartile: 57.63 ng / ml, 75% quartile: 129.32 ng/ml) (p<0.001). The rate of Serum Pepsinogen I (≤ 70 ng/ml) was 78.1% in patients with gastric cancer, was 26.7% in the control group. Serum Pepsinogen I test in cut-off value ≤ 70 ng/ml had a sensitivity of 78.1%, specificity 73.3%, positive predictive value of 75.8% and the predictive value negative of 75.9% (p <0.001). The results of the ROC curve: area under the curve = 0.846,p <0.0001 at the cut-of of Pepsinogen I levels in our study ≤ 50.83 ng/ml with the optimal sensitivity and specificity were 65.6% and 86.7%. Key words: serum Pepsinogen I, gastric cancer

The expression levels of miR-655-3p, miR127-5p, miR-369-3p, miR-544a in gastric cancer

2019 ◽  
Vol 44 (4) ◽  
pp. 487-491 ◽  
Author(s):  
Hani Alsaadoni ◽  
Burcu Çaykara ◽  
Sadrettin Pençe ◽  
Halime Hanım Pençe ◽  
Süleyman Bademler
Keyword(s):  
Gastric Cancer ◽  
Genetic Factors ◽  
Fold Change ◽  
Control Group ◽  
Expression Levels ◽  
Cancer Group ◽  
Chromosome 14Q32 ◽  
Polymerase Chain ◽  
Gastric Cancer Group ◽  
Gene Expression Levels

Abstract Background Gastric cancer, one of the most common cancers in the world, is a multifactorial disease in which environmental and genetic factors play a role. In our study, we aimed to determine the expression levels of four miRNAs (miR127-5p, miR-544a, miR-369-3p and miR-655-3p) on chromosome 14q32 in gastric cancer. Materials and methods Total RNA was isolated from blood samples taken from 66 gastric cancer and 66 healthy individuals. The gene expression levels determined by cDNA and quantitative real-time polymerase chain reaction were analyzed according to the 2−∆∆Ct method. SPSS 22 were used for statistical analysis and p < 0.05 was considered as statistically significant. Results and discussion miR-655-3p (fold change: 100, p = 0.026), miR-127-5p (fold change: 48, p < 0.001) and miR-369-3p (fold change: 1.6, p > 0.05) was less expressed in the gastric cancer group than control group. miR-544a was found 15.5-fold more expressed in the patient group than control group (fold change: 15.47, p < 0.001). Conclusion miR127-5p, miR-544a, and miR-655-3p may be evaluated as biomarkers in gastric cancer.

Copper and zinc in stage I multiple myeloma: relation with ceruloplasmin, lipid peroxidation, and superoxide dismutase activity

2018 ◽  
Vol 37 (3) ◽  
Author(s):  
Mohammad-Hassan Khadem-Ansari ◽  
Mojtaba Asoudeh ◽  
Hosein Fallahi Kord Gheshlaghi ◽  
Samira Nozari ◽  
Mina Zarringol ◽  
...  
Keyword(s):  
Lipid Peroxidation ◽  
Multiple Myeloma ◽  
Superoxide Dismutase ◽  
Absorption Spectrometry ◽  
Serum Levels ◽  
Stage I ◽  
Control Group ◽  
Sod Activity ◽  
Significant Difference ◽  
Serum Zn

Abstract Background The main aim of this study was to assess the serum levels of copper (Cu), zinc (Zn) with lipid peroxidation, Cu/Zn superoxide dismutase (Cu/Zn SOD) activity, and ceruloplasmin (Cp) in multiple myeloma (MM) patients. Materials and methods The study was conducted in 34 MM patients at stage I. Serum Cu and Zn levels were measured by atomic absorption spectrometry. Also, spectrophotometric assays of malondialdehyde (MDA) levels in addition to Cp and Cu/Zn SOD were quantitated. Results The results showed a significant decrease in the serum Zn levels in patients with MM (p < 0.0001). Also, serum Cu levels were significantly higher (p < 0.0001). However, the serum Cu/Zn ratio was significantly higher in the cancer patients (p < 0.0001). A significant difference was observed in the patients group compared with the control group according to the Cu/Zn SOD activity (p < 0.0001). Moreover, serum levels of Cp and MDA were significantly increased in patients (p < 0.0001, both). Conclusions The elevated levels of serum Cu and MDA with a decrease in Zn and Cu/Zn SOD might explain the increased oxidative stress in MM disease. As the high Cu level was observed in MM patients, therefore, Cu levels should be concentrated in the pathogenesis and progression of MM disease.

scholarly journals Diagnostic value of MRI-DWI signal intensity value combined with serum PGI, PGII and CA199 in early gastric cancer

2021 ◽  
Vol 67 (2) ◽  
pp. 95-100
Author(s):  
Minhong Li ◽  
GuangHui Zheng ◽  
Lin Yu ◽  
Li-lian Tan ◽  
Xi Li ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Early Gastric Cancer ◽  
Signal Intensity ◽  
Statistical Significance ◽  
Gastric Wall ◽  
Diagnostic Value ◽  
Wall Thickening ◽  
Healthy Group ◽  
Cancer Group ◽  
Gastric Cancer Group

To explore the diagnostic value of MRI-DWI signal intensity value combined with serum PGI. PGII and CA199 in early gastric cancer. Sixty cases of gastric cancer patients admitted to our hospital from December 2019 to December 2020 were selected as the gastric cancer group and 80 cases of healthy volunteers who underwent physical examination in our hospital during the same period were selected as the healthy group. All the 60 patients underwent MRI-DWI examination, and the pathological diagnosis results were regarded as the gold standard. MRI-DWI images, MRI-DWI signal intensity values of patients with different degrees of gastric cancer differentiation. Serum PGI, PGII and CA199 levels of subjects in the two groups were compared. AUC was used to evaluate the diagnostic value of MRI-DWI signal intensity value combined with serum PGI, PG II and CA199 for early gastric cancer. In the healthy group, T1W1 showed relatively uniform low signal intensity. While T2WI showed no significant increase in signal intensity. In the gastric cancer group. There was diffuse gastric wall thickening, local thickening or mass formation; T1WI and WATS showed slightly lower signal intensity in the lesion area. T2WI, FLAIR and B-TFE showed slightly uneven or moderately increased signal intensity. DWI showed limited diffusion, and the signal intensity increased uniformly or more uniformly, and the range of increase was clear. The signal intensity of MRI-DWI was 89.12 ± 8.14 in patients with low differentiation, 82.17 ± 6.35 in patients with moderate differentiation, and 74.52 ± 4.53 in patients with high differentiation. There were significant differences in the signal intensity of MRI-DWI among the three groups, and the difference was statistically significant (F=12.214, P <0.05). Serum PGI levels of subjects in the gastric cancer group were significantly lower than those in the healthy group, and the levels of PGII and CA199 were significantly higher than that in the healthy group, with statistical significance (P <0.05). The AUC, sensitivity and specificity of MRI-DWI signal intensity value and serum PGI, PGII and CA199 combined indexes in the diagnosis of gastric cancer were significantly higher than those of the independent indexes, with statistical significance (P <0.05). Conclusion: MRI-DWI signal strength value, serum PGI, PGII and CA199 levels are closely related to the occurrence and development of early gastric cancer. The combined detection and diagnosis efficiency is higher, which is helpful to improve the detection rate of early gastric cancer and is worthy of extensive clinical application.

scholarly journals Study on Blood Metabolomics of Early Gastric Cancer Based on Liquid Chromatography-Mass Spectrometry Technology

2021 ◽  
Author(s):  
Shanshan Qin ◽  
Qiong Wu ◽  
Rui Su ◽  
Wei Li ◽  
Yang Zhang ◽  
...  
Keyword(s):  
Mass Spectrometry ◽  
Gastric Cancer ◽  
Early Gastric Cancer ◽  
Diagnostic Ability ◽  
Blood Samples ◽  
Cancer Group ◽  
Heparin Sulfate ◽  
Group A ◽  
Group B ◽  
Gastric Cancer Group

Abstract Background: Metabolomics is widely used to accurately find the basic characteristics and material basis of life activities. The purpose of this study is to use metabolomics to discover biomarkers for the diagnosis of early gastric cancer.Methods: We collected the blood samples and clinical data of 63 patients with gastric cancer from the First Hospital of Jilin University, including 26 patients with advanced gastric cancer (group A), 37 patients with early gastric cancer (group B), and 18 healthy volunteers (group C). Chromatography-mass spectrometry (LC-MS) is used for detect metabolites and obtain metabolic profile. Support vector machine (SVM) is used to screen the differential metabolites with a weight of 100% from the blood sample. Total ion current diagram, principal component analysis and analysis of variance (ANOVA) are used to identify differential metabolites. PCA and the quadratic discriminant analysis were used to evaluate the similarity between samples. The receiver characteristic curve (ROC) is used to evaluate the diagnostic ability of metabolites. After the nuclear ratio of the selected metabolites is imported into the Human Metabolome Database (HMDB), the structure is identified to determine the corresponding substances, and then the verification group is used to test the accuracy of the metabolites.Results: Through LC-MS, TIC, ANOVA and PCA, differential metabolites were found in different blood samples. Cluster analysis showed similar metabolites in the three groups A, B, and C. ROC curve represented the diagnostic ability of metabolites. The different metabolites between group A and C were spermine, enterostatin, heparin sulfate, and triacylglycerol. The difference metabolites between group A, group B and group C were same as those between group A and C. The cluster analysis and ROC also showed that all four metabolites had high specificity and sensitivity in the verification group. And the results of verification group were consistent with the experimental group.Conclusion: Spermine, enterostatin, heparin sulfate, and triacylglycerol may be potential biomarkers for the diagnosis of early gastric cancer.

scholarly journals Clinical significance of Serum Pepsinogen I/II and gastrin-17 determination in gastric cancer diagnosis and prognosis

2018 ◽  
Vol 16 ◽  
pp. 205873921878129 ◽  
Author(s):  
Huiguang Xue ◽  
Aihua Yang ◽  
Fuguo Liu ◽  
Xueguo Sun ◽  
Xishuang Liu
Keyword(s):  
Gastric Cancer ◽  
Gastric Ulcer ◽  
Control Group ◽  
Serum Pepsinogen ◽  
Gastric Function ◽  
Pepsinogen I ◽  
Diagnosis And Prognosis ◽  
Cancer Group ◽  
Ulcer Group ◽  
Gastric Cancer Group

Currently, the diagnosis of atrophic gastritis and gastric cancer are mainly made by endoscopy and histopathology. Our study aimed to explore the practical value of Serum Pepsinogen I/II and gastrin-17 in gastric cancer diagnosis and prognosis. We collected 60 cases of gastric ulcer from February 2015 to November 2016 as gastric ulcer group, and 40 cases of gastric cancer treated in the same period as gastric cancer group. In 3  years after gastric cancer, 20 patients were served as postoperative gastric cancer group, and 70 healthy subjects as control group. The results showed that serum Pepsinogen I/II, gastrin-17, and other serum gastric function indexes were tested by enzyme-linked immunosorbent assay (ELISA). The serum PGI level of gastric ulcer group was higher than control group ( P  <  0.05). The serum G-17 concentrations in gastric ulcer group, gastric cancer group, and postoperative gastric cancer group were all higher than control group ( P  <  0.05). The area under receiver operating characteristic (ROC) curve of PGI screening was 0.905 and the best cutoff point was PGI  <  75  µg/L. Their sensitivity and specificity were 87.2% and 75.1%; the area under ROC curve of PGI/PGII rate screening was 0.761 and the best cutoff point was PGI/PGII  <  4. Their sensitivity and specificity were 88.9% and 62.3%. Multi logistical regression showed that the level of serum PGI, PGI, and G-17 and the odds ratio (OR) level of gastric cancer risk were 2.093, 2.653, and 0.494 ( P  <  0.05). The examination of Serum Pepsinogen I/II, gastrin-17, and other serum gastric function indexes can be used in the diagnosis and prognosis of gastric cancer and has a rather high practical value in monitoring recurrence in postoperative gastric cancer patients.

Sign in / Sign up

Export Citation Format

Share Document